Zidovudine: A targeted therapy for endemic Burkitt's lymphoma

East African Medical Journal

Volumn 82, Issue 9 SUPPL., 2005, Pages

  Kurokawa, M ^a   Andela, V ^a   Ghosh, S ^a   Barreto, J Enrique ^b   Harrington, W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

AFRICA; ARTICLE; BRAZIL; BURKITT LYMPHOMA; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EPSTEIN BARR VIRUS; GENE TARGETING; GENETICS; HUMAN; META ANALYSIS; ONCOGENE; VIROLOGY; VIRUS INFECTION;

AFRICA; ANTIVIRAL AGENTS; BRAZIL; BURKITT LYMPHOMA; DEVELOPING COUNTRIES; DRUG DELIVERY SYSTEMS; EPSTEIN-BARR VIRUS INFECTIONS; GENE TARGETING; HERPESVIRUS 4, HUMAN; HUMANS; ONCOGENES; ZIDOVUDINE;

EID: 33744477921     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Knowles, D.M. Biology of non-Hodgkin's lymphoma. Cancer Treat Res. 2001; 104:149-200.
2. Spreafico, F, Massimino, M, Luksch, R, Casanova, M. et al. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J. Clin. Oncol. 2002; 20:2783-2788.
3. Young, L.S. and Murray, P.G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003; 22:5108-5121.
4. Jacobs, P. The malignant Iymphomas in Africa. Hematol. Oncol. Clin. North Am. 1991; 5:953-982.
5. Yano, T., Sander, A. C., Clark, M. H., et al. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene. 1993; 10:2741.
6. Willis, T.G. and Dyer, J.S. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000; 96:808-819.
7. Sen, R. NF-KB and the immunoglobulin K gene enhancer. J. Exp. Med. 2004; 200:1099-1102.
8. Tergaonkar, V., Pando, M., Vafa, O., et al. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell. 2002; 5:493-503.
9. Karin, M., Cao, Y., Greten, F.R. and Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002; 2:301-310.
10. Baldwin, A.S. Jr. The NF-kappa Band I kappa B proteins: new discoveries and insights. Ann. Rev. Immunol. 1996; 14:649.
11. Geronakis, S., Grossman, M., Nakamur, Y., et al. Genetic approaches to understand Rel/NFkB and IkB function: transgenics and knockouts. Oncogene. 1999; 18:6888-6895.
12. Liou, H-C. and Hsia, C.Y. Distinctions between c-Rel and other NFkB proteins in immunity and disease. Bio. Essays. 2003; 25:767-780.
13. Karin, M. How NFkB is activated: the role of the IkB kinase (IKK) complex. Oncogene 1999; 18:6867-6874.
14. Sha, W.C. Regulation of immune responses by NFkB/Rel transcription factors. J. Exp. Med. 1998; 187:143-146.
15. Brown, HJ, Song, M. J., Deng, H, W.u T. T. Cheng, G., and Sun, R. NF-kappaB inhibits gammaherpesvirus lytic replication. J. Virol. 2003; 77:8532-8540.
16. Leight, E.R. and Sugden, B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev. Med. Virol. 2000; 10:83-100.
17. Touitou, R., Arbach, H., Cochet, C., et al. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. J. Gen. Virol. 2003; 84:949-957.
18. Muller, J.R. and Siebenlist, U. Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J. Biol. Chem. 2003; 278:12006-12012.
19. Prince, S., Keating, S., Fielding, C., Brennan, P., Floettmann, E. and Rowe, M. Latent membrane protein I inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J. Virol. 2003; 77:5000-5007.
20. Davis, R.E., Brown, K.D., Siebenlist, U. and Staudt, L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B. cell-like differente large B. cell lymphoma cells. J. Exp. Med. 2001; 194:1861-1874.
21. Cahir-McFarland, E.D., Davidson, D.M., Schauer, S.L., Duong, J. and Kieff, E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc. Natl. Acad. Sci. USA. 2000; 97: 6055-6060.
22. Keller, S.A., Schattner, E.J. and Cesarman, E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000; 96:2537-2542.
23. Mentzer, S.J., Fingeroth, J., Reilly, J.J., Perrine, S.P. and Faller, D.V. Arginine butyrate induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol. Dis. 1998; 24:114-123.
24. Israel, B.F. and Kenney, S.C. Virally targeted therapies for EBV-associated malignancies. Oncogene. 2003; 22:5122-5130.
25. Feng, W. H., Israel, B., Raab-Traub, N., et al. Chemotherapy induces lyric EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 2002; 62:1920-1926.
26. Kurokawa, M., Ghosh, S.K., Ramos, J.C., et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005; 106:235-243.
27. Harrington, W.J. Jr, Cabral, L., Cai, J.P., et al. Azidothymidine and interferon-alpha are active in AIDS-associated small non-cleaved cell lymphoma but not large-cell lymphoma. Lancet. 1996; 248:833.
28. Raez L Cabral L. Cai, J.P., et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res. Hum. Retroviruses. 1999; 15:713-719.
29. Aboulafia, D.M. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin. Infect. Dis. 2002; 34:103-115.
30. Royehowdhury, S., Peng, R., Baioechi, R. A., et al. Experimental treatment of Epstein Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003; 63:965-971.
31. Ghosh, S. K., Wood, C., Boise, L. H., et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood. 2003; 101:2321-2327.
32. Toomey, N. L., Deyev, V. V., Wood, C. et al. Induction of TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene. 2001; 20:7029-7040.
33. Giacca, M., Borella, S., Calderazzo, F. et al. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3′-azido-3′- deoxythymidine on HIV type 1 infection in vitro. AIDS Res. Hum. Retroviruses. 1996; 12:677-682.
34. Sandlund, J.T., Fonseca, T., Leimig, T., et al. Predominance and characteristics of Burkitt lymphoma among children with non-Hodgkin lymphoma in northeastern Brazil. Leukemia. 1997; 11:743-746.
35. Klumb, C.E., Schramm, M.T., De Resende, L.M. et al. Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J. Paediatr. Hemetol. Oncol. 2004; 26:462-468
36. Gutierrez, M.I., Bhatia, K., Barriga, F., Diez, B. et al. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood. 1992; 79:3261-3266.
37. Xue, S.A., Labrecque, L.G., Lu, Q.L. et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int. J. Cancer. 2002; 99:635-643.
38. Kelly, G., Bell, A. and Rickinson, A. Epstein-Barr virus-associated Burkitt lymphoma selects for down regulation of the nuclear antigen EBNA2. Nat. Med. 2002; 8:1098-1104.